See Why ResMed (RMD) Has a Margin of Safety

Medical Instruments & Supplies firm ResMed is one of the rare companies that fulfills most of Graham’s requirements for a defensive high-quality stock.

At Market Inference, we adhere to Benjamin Graham’s view that precise forecasting of a company’s prospects is highly uncertain. Investing with a wide margin of safety, determined on the basis of the company’s historical track record, offers far greater chances of positive investment results.

ResMed Is Probably Overvalued

Graham devised the below equation to give investors a quick way of determining whether a stock is trading at a fair multiple of its earnings and its assets:

√(22.5 * 4 year average earnings per share (4.66) * 4 year average book value per share (28.082) = $54.26

At today's price of $177.03 per share, ResMed is now trading 226.2% above the maximum price that Graham would have wanted to pay for the stock.

Even though the stock does not trade at an attractive multiple, it might still meet some of the other criteria for quality stocks that Graham listed in Chapter 14 of The Intelligent Investor.

Impressive Revenues, Consistent Profitability, and a Growing Dividend Imply Value

ResMed’s average sales revenue over the last 4 years has been $3.49 Billion, so by Graham’s standards the stock has sufficient revenues to make it worthy of investment. When published in 1972, Graham’s threshold was $100 million in average sales, which would be the equivalent of around a half million dollars today.

Ben Graham believed that a margin of safety could be obtained by investing only in companies with consistently positive retained earnings. Retained earnings represent the cumulative net earnings or (deficit) left to equity holders after dividends have been paid out. ResMed had positive retained earnings from 2010 to 2023 with an average of $2.27 Billion over this period.

Ben Graham would also require a cumulative growth of Earnings Per Share of at least 30% over the last ten years.To determine ResMed's EPS growth over time, we will average out its EPS for 2009, 2010, and 2011, which were $0.95, $1.23, and $1.44 respectively. This gives us an average of $1.21 for the period of 2009 to 2011. Next, we compare this value with the average EPS reported in 2021, 2022, and 2023, which were $3.24, $5.30, and $6.09, for an average of $4.88. Now we see that ResMed's EPS growth was 303.31% during this period, which satisfies Ben Graham's requirement.

ResMed’s Balance Sheet Meets Graham’s Criteria

It was also essential to Graham that the company’s current assets outweigh its current liabilities, and that its long term debt be inferior to the sum of its net current assets (current assets minus total liabilities). This is the aspect of the analysis that most companies fail, yet ResMed passes comfortably, with an average current ratio of 3.1, and average debt to net current asset ratio of -5.6.

Conclusion

Graham is best known for the Graham number valuation method, and his net-net strategy of investing in a broad portfolio of companies that trade below their net current asset value. But these approaches are too narrow, and fail to capture the full scope of Graham’s statistical approach to stock picking.

ResMed offers a rare combination of value, growth, and profitability. So it comes as no surprise that the company isn’t cheap enough to meet Graham’s definition of a net-net, and that it does not trade, on average, far below its Graham number. Rather, ResMed is an interesting company because it meets Graham’s broader definition of quality.